|
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
- Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual Current disease-modifying therapies for multiple sclero
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Tirzepatide and semaglutide are highly effective medications for obesity management The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early . . .
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management Additional data on the efficacy and
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
- Lepodisiran - The New England Journal of Medicine
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa
|
|
|